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Abstract
Background: Personalized medicine (PM) aims to tailor disease prevention, diagnosis, and treatment to individuals
on the basis of their genes, lifestyle and environments. Patient and interest organizations (PIOs) may potentially play
an important role in the realization of PM. This paper investigates the views and perspectives on PM of a variety of
PIOs.
Methods: Semi-structured telephone interviews were conducted among leading representatives of 13 PIOs located
in Europe and North-America. The data collected were analysed using a conventional content analysis approach.
Results: The PIO representatives supported the realization of PM but feared that many financial, structural and
organizational challenges may delay its realization. They encouraged strategies to modernize drug licencing
mechanisms, develop research and data sharing infrastructures, and educate patients and health care professionals
in PM. Notably, they emphasized the importance of developing PM in an equitable way and taking into consideration
the patients’ needs, values and personal situation. Despite varying levels of awareness regarding PM, the PIO
representatives expressed willingness to engage in the PM agenda and recommended that PIOs work closely
with policy-makers to design PM in a way that truly addresses the needs and concerns of patients.
Conclusions: PIOs have the potential to become central drivers of the PM agenda. Collaborations should be further
developed between PIOs, researchers, drug developers and health care authorities.
Keywords: Personalized medicine, Patient organizations, Genetics, Ethics, Precision medicine
Background
Recent advances in biomedical research and biotechnol-
ogy offer new possibilities to tailor prevention, diagnos-
tic and treatment to the specific needs of patients. By
utilizing information about the patients’ genetic and mo-
lecular profile combined with their family history and
clinical and environmental data, it is hoped that health
care providers will be able to start interventions earlier
and select therapies that are more precise, efficient and
provide less side-effects – strategies broadly known as
personalized medicine (PM) [1]. Large investments are
being made worldwide to support such strategies. In the
United States, the $215 million Precision Medicine
Initiative [2] was recently launched with the objective
to accelerate biomedical discoveries and improve the
effectiveness of treatment. In Europe, the European
Commission has since 2007 committed over €1 billion of
health research funding to the development of ‘-omics’
technologies and targeted therapies, and more funds are
expected to be released in the coming years [3]. PM has
been extensively described in recent reports from national
and international medical organizations and funders
[4–6]. These reports emphasise the importance of en-
gaging a variety of stakeholders such as health care
providers, biomedical researchers, regulators, drug de-
velopers, patients and patient organizations in driving
PM forward. Among these stakeholders, patient orga-
nizations are particularly valuable players regarding
their role in patient education [7], assessing new bio-
medical developments [8], and supporting research
projects [4]. However, with the exception of recent
surveys in which patient organizations identified potential
barriers in PM implementation [9] and key priority areas
within cancer [10], little empirical data are available to
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document the views and perspectives of patient organiza-
tions on PM.
Investigating how patient organizations perceive PM
and which role they are willing to play in its realization
is important for several reasons. First, patient organiza-
tions have close contact with the communities of pa-
tients they represent. They are therefore well-placed to
provide qualified opinions regarding how to implement
PM in a way that addresses the needs and concerns of
these communities. For instance, PM may require that
patients learn about their genetic risk profile, engage
more actively in the medical decision-making process
and share their health data with researchers and clini-
cians more broadly than conventionally practised [11].
Patient organizations are well-qualified to familiarize
patients and communities with such developments.
Second, patient organizations may provide useful guid-
ance in addressing potential ethical and societal chal-
lenges that may arise when new medical approaches are
implemented. For instance, PM may imply that patients
are offered differential access to treatment depending on
their genetic profile [12]. Patient organizations may be
well placed to explore how dialogue with patients and
communities should take place when access to conven-
tional treatment may be restricted. Third, patient organi-
zations have comprehensive expertise within the areas of
patient and health care professional capacity building
[13, 14], the development of online patient communities
[15], the design of regulatory frameworks and patenting
policies [16], the financing and management of clinical
trials and biobanks [15, 17–19], and more recently, in
developing databases and web-based platforms for
patient-driven data sharing [13, 20]. Making use of these
skills and experiences may accelerate the realization of
PM.
Although patient organizations are often referred to as
one homogenous group, they are rather a constellation
of entities that vary considerably in size, organizational
structure, denomination and mandate [13]. For instance,
patient organizations may be publicly or privately-
funded, small entities which represent only a limited net-
work of families suffering from a particular condition, or
they may be large-scale, international organizations
bringing together national organizations which focus on
one specific disease or specialize in improving the living
conditions of all patients. We conducted a qualitative
interview study among leading representatives of non-
profit patient organizations which are concerned with
one specific disease or disease area and define them-
selves as patient advocacy organizations, umbrella orga-
nizations for patient advocacy organizations or interest
organizations, hereafter referred to as patient and inter-
est organizations (PIOs). The objective of our study was
to collect information about three main issues: 1) the
PIOs’ views and perspectives on PM, 2) recommenda-
tions for facilitating the realization of PM, and 3) the
role they foresee that they may play in the realization of
PM.
Methods
Recruitment of study sample
To collect information about the views of a variety of
PIOs, we proceeded in two steps. First, in July 2014, we
sent an e-mail invitation to the leaders of a small num-
ber of PIOs that co-operate with the research network of
the Norwegian Cancer Genomics Consortium (NCGC)
[21], a national research platform aiming to establish
personalized clinical strategies for cancer treatment in
Norway. The email invitation provided an outline of the
study objectives and a description of what participation
in the study entailed. In the invitation, PM was described
as “an emerging practice of medicine that uses an indi-
vidual’s genetic profile to guide decisions made with
regard to the prevention, diagnosis, and treatment of
disease” as defined in the Talking Glossary of Genetic
Terms of the National Human Genome Research Institute
[22]. The email invitation included a request for written
informed consent. The study was approved by the
Norwegian Social Science Data Services.
The first PIO leaders who accepted our invitation
helped us identify other PIO representatives that might
want to participate in the study. Through such snowball
sampling, we were able to recruit representatives from 8
PIOs concerned with one specific disease or disease area
(6 PIOs in Norway, 1 in the United Kingdom and 1 in
the USA) between July 2014 and January 2015. In paral-
lel and in order to extend our sampling, we sent email
invitations to 20 leaders of disease-specific PIOs mem-
bers of the European Patients’ Forum (EPF) [23], an um-
brella organisation of pan-European patient advocacy
organizations. The PIO representatives were recruited in
the study until a point of saturation was attained, i.e.
when no significant new information was collected. Five
PIO representatives agreed to join the study, six
responded that they did not have time to participate or
did not want to participate, and nine did not respond to
our invitation. In total, thirteen PIOs working within the
areas of cancer (4), hereditary and genetic disorders (3),
mental health (1), diabetes (1), psoriasis (1), AIDS (1),
lupus (1), and primary immunodeficiencies (1) partici-
pated in the study (Table 1). The representatives inter-
viewed were organizational leaders (10) (e.g. CEO,
secretary general, director) and senior managers (3)
employed by the PIOs. As leading representatives of
their PIOs, they were able to speak on behalf of their
organization although many specified that their
organization did not have an official position on PM.
The size of the PIOs varied from small PIOS gathering
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families suffering from a rare genetic disorder to large
PIOs gathering more than a thousand organizational
members.
Data collection and analysis
Semi-structured telephone interviews were conducted
with the thirteen PIO representatives, lasting forty
minutes on average. An interview guide was used to
lead the conversation, which included open-ended
questions about the PIOs’ perspectives regarding PM,
PM-related activities, perceived challenges with regard
to the realization of PM, recommendations for the
adoption of PM, and the potential roles the PIOs may
play in the realization of PM. The interviews were
conducted in English or Norwegian by the first au-
thor trained in qualitative methods and fluent in both
languages. The interviews were audio recorded and
transcribed verbatim in English and Norwegian. The
transcripts were analysed manually by the first author
using a qualitative content analysis approach in an in-
ductive way [24]. First, a thematic analysis of the
interview texts was conducted to identify overarching
themes that emerged from the responses to each
open-ended question formulated in the interview
guide. Next, the substantive content of the text was
extracted, coded and categorized according to the
overarching themes. If new codes were identified, the
coding frame was updated accordingly. Then, the text
pertaining to each of these themes was condensed to
reflect the main points raised by the PIO representa-
tives. In August 2015, a two-page report summarizing
the main findings was sent by email to the PIOs rep-
resentatives for validation. Their comments and cor-
rections to the report were integrated in the results.
Results
The PIO representatives described their interest in PM
and potential challenges that may impede or delay the
realization of PM. Particular emphasis was put on pos-
sible side effects of focusing on PM strategies. Then, the
representatives made a number of recommendations for
the realization of PM and discussed how their organiza-
tions may contribute to the PM endeavour.
PIOs interest in PM
Overall, the PIO representatives expressed interest in
PM. They explained that the current medical needs of
their patient groups are largely unmet and medical strat-
egies which address issues of side effects, overtreatment
and undertreatment are strongly needed. As outlined by
this representative:
(1) If you create a medicine that directly targets the
individual, you will then be able to avoid all these
unsuccessful attempts to find the right treatment
without getting better, having to deal with the side
effects, the downturns, the disappointments (…) when
you use a medicine that has side effects for a long
period, you are sick for months and then it turns out
that [the medicine] does not help anyway. Developing
medicines that will perhaps work at once and not
after the fifth attempt, (…) we see this as perhaps the
most important thing to achieve.
However, several representatives confessed that PM
was a topic that had not been thoroughly discussed in
their organization. Most PIOs did not use the terms PM
and did not specifically mention PM in their strategic
documents with the exception of some cancer PIOs.
Table 1 PIOs participating in the study
PIO name Membership Country
DEBRA Hrvatska (Dystrophic Epidermolysis Bullosa Research Association) Approx. 50 families Croatia
Genetic Alliance UK >100 organizational members UK
Genetic Alliance USA >1,000 organizational members USA
LUPUS Europe Approx. 22 country memberships Denmark
Sarcoma Approx. 350 individual members Norway
The European AIDS Treatment Group Approx. 110 individual members Belgium
The European Umbrella Organisation for Psoriasis Movements (EUROPSO) Approx. 20 country memberships Norway
The International Patient Organisation for Primary Immunodeficiencies (IPOPI) Approx. 55 country memberships UK
The Norwegian Breast Cancer Society Approx. 14,500 individual members Norway
The Norwegian Cancer Society Approx. 113,000 individual members Norway
The Norwegian Childhood Cancer Organization >3,000 individual members Norway
The Norwegian Council for Mental Health Approx. 29 organizational members Norway
The Norwegian Diabetes association Approx. 40,000 individual members Norway
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Several representatives also explained that the concept
of PM and its possible practical implications were still
unclear. As an illustration, one representative believed
that PM meant that health care professionals allocate
more face-to-face time with each patient.
PM challenges
High cost of PM
Most representatives feared that PM may be too expen-
sive for many health care systems which are currently
dealing with significant financial constraints. They expe-
rienced that patient access to conventional treatment is
increasingly restrained due to cost issues, and observed
that new targeted drugs that are launched on the market
are so highly-priced that patients can hardly afford them
unless their cost is fully covered by payers. As expressed
by this representative:
(2) If we end up with the same level of cost to get
an authorization for a targeted drug that would
effectively treat 10% of a population of people with
a given disease, rather than being used to treat a
100% of the population with a given disease, then
the cost for (…) personalized medicine per patient
treated will have to be higher.
Although the representatives acknowledged PM’s po-
tential to save costs as treatment becomes more targeted
and waste is avoided, they expected PM to require signifi-
cant up-front capital investments in equipment and infra-
structures that most countries cannot afford. They also
suspected that PM may lead to increased medical follow-
up as genetic tests are more frequently used in clinical set-
tings to confirm a diagnostic. Another concern was that
patients who purchase genetic testing kits from direct-to-
consumer genetic testing companies may seek medical
advice from their physician to interpret the results, thus
creating additional burdens on health care services.
Lack of health literacy
Several PIO representatives expressed scepticism regard-
ing the patients’ ability to understand and endorse PM
strategies. They noted that patients often struggle to
understand basic medical information:
(3) People do not understand information well
enough, this is where we see a big job for the patient
organizations and patient groups in each of the
countries in Europe, (…) educate, bring awareness of
how important (…) the different kinds of medications
are, when they are supposed to be used and for what,
(…) there is a reason why it has been prescribed (…).
There is a huge communication aspect that we have
just picked up.
Another representative suspected that many patients
are not ready to learn about their genetic profile, in par-
ticular if unexpected findings are discovered:
(4) Genetic testing for rare genetic conditions and
other disorders can now be performed in hospitals,
you can get some answers that are incidental and that
no one asked for and for which a decision must be
made. We think that this is a challenge (…), the
patients are not aware of this. They can get a lot of
information that is hard to digest.
These views were however nuanced by the perspec-
tives of other representatives who emphasized that pa-
tients who have been waiting for a diagnostic for many
years are often eager to learn about their genetic profile.
Several PIO representatives also explained that general
practitioners often do not understand the specificities of
disease, and suspected that many are insufficiently
trained in genetics to use PM strategies in their medical
practice. Similarly, several representatives explained that
policy-makers often do not understand why patients
need specific types of treatment rather than a “one-size-
fits-all” treatment.
Lack of mechanisms and infrastructures to support PM
Several PIO representatives explained that current drug
licensing mechanisms unnecessarily delay the launching
of personalized treatments. Receiving drug approval
from regulatory authorities often takes years and is par-
ticularly cumbersome if such approval is needed across
borders. Although the representatives largely believed
that data protection regulations are needed to protect
the rights and interests of patients, some representatives
suspected that such regulations may be too stringent
and hinder the conduct of biomedical research. As
expressed by this representative:
(5) When it comes to access to this information in
relation to biobanks, there are so many rules already
dealing with this, I know that many are concerned
about this (…), but what is it we are scared about?
There are rules for how [information] can be
managed and used, I do not see any danger that
[information] will be misused.
Unwanted consequences of PM
In general, the PIO representatives worried that PM, be-
cause of its high costs, may reinforce already existing
health care disparities among social groups unless spe-
cific measures are taken by policymakers to enable
equitable access to PM. Some representatives also
expressed concerns that patient groups may be forgotten
if they represent a genetic subset that is not considered
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lucrative by pharmaceutical companies. As expressed by
one representative:
(6) If it is really individualized, if it’s really about
genetics, there will be populations that will be
marketwise less interesting, maybe population-wise
they are, meaning that you should not only look at
the benefit for the rich white community but also for
the populations that are maybe research-wise less
interesting to include but might really benefit from
more research.
Some representatives feared that the increased use of
technology in health care may lead professionals to re-
duce patients to their genetic profile. As described by
this representative:
(7) I think it is essential that the patient remains at
the center and that he doesn’t become a data or an
entity; it’s really a patient and a face and the [health
care professionals] need to treat that patient, that’s the
main goal.
Genetic discrimination was a shared concern of some
representatives. An example was provided of patients
being denied health insurance because of their medical
history even if the law prohibits such practice. As
expressed by one representative:
(8) If we, sometime in the future, find genes that you
would like to have and genes you would prefer not
having, it is clear that it may contribute to creating
A-people and B-people. From the moment our genes
become a question of value, it may create differences
between people. Some people may be worth more
than others and then we are back to the 30’s, so from
a historical point of view, this is important.
Finally, one representative worried that priority may
be given to genetic research, not because it may lead to
the most useful results, but because it is technologically
exciting and may benefit the commercial interests of
pharmaceutical companies. This representative empha-
sized the importance of also conducting other types of
research such as social and behavioural research.
Main recommendations for the realization of PM
The PIO representatives made recommendations for the
realization of PM that can be assigned to five main cat-
egories as described below and summarized in Table 2.
Policy-making
Overall, the representatives emphasized the importance
of providing equitable access to PM. They explained that
access to genome sequencing technologies and targeted
drugs should not be limited by financial constraints but
offered according to specific priority criteria that are
jointly established by policymakers, health care profes-
sionals and patient representatives. They believed that
modernizing drug licensing mechanisms is necessary to
enable quicker access to targeted drugs. Adaptive path-
ways mechanisms were mentioned as a potential ap-
proach to improve timely access for patients to new
medicines [25]. The representatives also recommended
allocating specific funding to the implementation of PM,
for instance to develop necessary biobanks and data
sharing infrastructures. Some representatives suggested
Table 2 PIOs’ recommendations for the realization of PM
Recommendations
Policy-making
• Establish principles and criteria for equitable patient access to PM
• Modernize drug licensing mechanisms, e.g. through adaptive pathways
• Allocate specific funding to the implementation of PM
• Implement PM gradually, e.g. through pilot projects including the most
needy patients
Patient-centered health care
• Provide simple, actionable genetic information to patients; ally with
genetic counselors
• Take into consideration the patients’ values, personal situation and
health literacy level
• Protect the patient’s right not to know
• Educate patients and health care professionals in PM strategies
Increased, inclusive research
• Conduct more basic/epidemiological research
• Invite patients and PIOs early in the planning and design of clinical
trials
• Broaden eligibility criteria to recruit more patients in research
Data sharing and protecting privacy
• Develop privacy-solid biobanks and data sharing infrastructures
• Ask for permission before using personal health data
• Develop flexible and interactive consent mechanisms
PIOs’ active participation in agenda setting
• Engage as early as possible in the development of PM
• Contribute to educate stakeholders in PM
• Contribute to design the PM agenda, e.g. by identifying priority areas
• Support the development of collaborative research projects
• Respond to national hearings of relevance for PM
• Join research ethics committees and drug approval boards
• Develop partnerships with medical professions, e.g. through medical
expert panels
• Develop partnerships between PIOs nationally and internationally
• Develop partnerships between PIOs and researchers, medical
professions, and policy makers
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implementing PM gradually, starting with the patients
groups that are most in need such as those for whom no
established treatment currently exists.
Patient-centered health care
Most representatives emphasized the importance of an
open dialogue between health care professionals and pa-
tients. They believed that patients should be provided
with information that is simple, understandable, action-
able and adapted to the patient’s needs, values, level of
health literacy and way of dealing with disease. They ex-
plained that the value of an intervention should not only
be measured in medical, biological or scientific terms
but also in terms of how it impacts the patients’ quality
of life and ability to function in society, and recom-
mended that these aspects are taken into consideration
when assessing patient needs. They strongly recom-
mended providing genetic counselling to patients when
genetic information is available. In general, the represen-
tatives believed that the medical literacy of patients
should be improved. However, they explained that pa-
tients differ in their willingness to learn about their dis-
ease and engage in their health care, and that their
personal preferences, for instance regarding access to
their genetic information, should be respected. In
addition, the representatives considered it important to
educate health care professionals in PM strategies. In
contrast, educating the general public about PM was
seen as useful but not an absolute priority. The repre-
sentatives believed that public awareness about PM may
gradually develop as targeted treatments are becoming
more broadly available in health care.
Increased, inclusive research
In general, the representatives believed that more re-
search should be conducted to understand the causes
underlying disease, investigate the mechanisms of side
effects, explore the consequences of living a long time
with a specific treatment and develop strategies to im-
prove the quality of life of patients. They explained that
patients are willing to participate in medical research
but are often denied such opportunity because of strict
eligibility criteria. They recommended engaging patients
and patient representatives as early as possible in the
planning and design of clinical trials and broadening eli-
gibility criteria to include more varied populations across
socio-economic groups.
Data sharing and protecting privacy
The representatives supported the development of bio-
banks and data sharing infrastructures that are governed
by solid and transparent privacy protection frameworks
as these are essential to maintain the trust of patients
and protect their interests. Privacy protection was seen
as particularly important when the health data that are
shared originate from patients suffering from socially
stigmatizing diseases. The representatives explained that
more work is needed to make people comfortable with
sharing their personal health data.
PIOs’ active participation in agenda setting
The representatives believed that PIOs should be involved
as early as possible in the planning and design of the PM
agenda. They explained that the main role of PIOs in PM
includes helping to: a) increase literacy in PM among pa-
tients and health care professionals, b) identify the areas
in which PM is most needed, and c) support the develop-
ment of research projects that are attractive to patients.
The representatives envisioned increased collaboration
between PIOs and research groups, medical bodies, drug
developers and policy-makers, nationally and internation-
ally to encourage the development of PM. They also be-
lieved that patients and lay representatives should be
more frequently invited to join research ethics committees
and drug approval boards. The representatives recom-
mended the development of inter-PIOs collaborations to
enable the organizations which are more knowledgeable
about PM to help others join the PM endeavour. Finally,
they called for initiatives to educate PIOs in PM as finding
the right information about PM may be challenging and
many PIOs do not have a clear understanding of how they
can contribute to the successful realization of PM.
Discussion
Our findings show that PIO representatives had a posi-
tive although cautious attitude toward PM. They be-
lieved that PM is needed but suspected that many
financial, structural and organizational challenges may
delay its realization. Although the recommendations for-
warded by the representatives to support the realization
of PM are largely congruent with those made by the pro-
moters of PM [4–6], they also shed light on specific eth-
ical and societal challenges that may arise in the process
of adopting PM. Importantly, attention to these consid-
erations has not been emphasized in the public debate
but they should be addressed to enable the successful
realization of PM in a way that truly addresses the needs
and concerns of patients.
Developing PM in an equitable way, and involving dis-
cussions with decision-makers about how such equity
may be achieved, was seen as the main priority. The PIO
representatives based their rationale on the types of
problems that their patients encounter daily in health
care systems. For instance, the prices of new targeted
drugs have steadily increased during the last decade [26]
and health care systems frequently deny patients access
to such drugs because of financial constraints unless the
patients can pay out-of-pocket [27, 28]. The PIO
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representatives expressed concern that issues of social
injustice may arise if individuals who are more socio-
economically advantaged benefit most from new treat-
ments because they have the financial ability to pay for
them. The fundamental principle of equitable access to
health care may be threatened when “niche buster
drugs” designed for smaller groups of patients are more
expensive and therefore less accessible than blockbuster
drugs [28]. This issue has already been raised by coali-
tions of patient organizations which have called for an
equitable and universal patient access to PM independ-
ent of the patient’s socio-economic status and geograph-
ical location [9, 29, 30].
Although the PIO representatives emphasized that
equitable access to PM was critical, they did not articu-
late in detail what such equity should entail. Equity is a
broadly acknowledged ethical concept that is concerned
with the fair and impartial “distribution of benefits and
costs to distinct individuals or groups” [31]. Although
most health care systems strive to achieve equity, it has
shown to be difficult to operationalize. For instance, it is
usually considered as equitable to allocate health care re-
sources on the basis of consideration of the actual needs
of patients [32]. However, how to determine which
needs are most important, and how they should be pri-
oritized is often challenging. As an illustration, should
the needs of terminally ill patients be addressed in prior-
ity, or those of patients who may yield significant gains
in life expectancy if treatment is provided [33]? Two
PIO representatives mentioned that patients for whom
no standard treatment exists, for instance some groups
of cancer patients, should be prioritized to receive access
to genome sequencing in the hope that a potential treat-
ment may be found. However, neither the importance
nor the implications of providing genome sequencing to
cancer patients if little is known about the genes in-
volved in their cancer types are well understood. Other
criteria may also have to be taken into consideration for
resource allocation such as the efficacy and effectiveness
of the intervention (its ability to lead to a positive out-
come for the patient) and its cost-effectiveness (ability to
provide value for money) [34]. Even if it is seen as
morally justifiable to give priority to the patients who
are in greatest need, it may not be wise from a cost-
effectiveness perspective if the intervention is not ex-
pected to benefit the patient. Decision-makers are faced
with having to balance between these different consider-
ations (equity, efficacy, cost-effectiveness) and make
decisions that do not unjustifiably discriminate some
groups of patients. In the absence of a clear normative
framework providing guidance on how to distribute re-
sources fairly [35], it may be useful to investigate pro-
cesses that are deliberative, transparent, and “appeal to
rationales that all can accept as relevant to meeting
health needs fairly” [36]. This is where PIOs may play an
important role by collaborating with decision-makers in
order to find pragmatic solutions for an equitable and
reasonable resource allocation. As an illustration, the
Scottish Medicines Consortium convenes clinicians,
health economists and patient representatives to identify
and prioritize those medicines and interventions which
represent good value for money to patients and should
be launched on the market [37]. Such collaboration may
be good example of how a fair process may take place.
Taking into consideration patients’ interests and values
to a greater extent than traditionally practised was also
seen as critically important by the PIO representatives.
PM is often described as a holistic approach to medicine
that utilizes information about the patient’s clinical and
family history, genetic susceptibility to disease, response
to certain drugs, and lifestyle to assess the patient’s
health [4–6]. The PIO representatives interpreted the
meaning of “personalized” medicine slightly differently
from the promoters of PM. Although the PIO repre-
sentatives largely agreed that focusing on the bio-
logical and environmental factors that may affect the
health of the patient is important, they also believed
that “personalizing” health care means that greater atten-
tion should also include taking the time to listen to the
patient, learn about her values, assess her mental and spir-
itual well-being, understand her personal circumstances,
and improve her quality of life and ability to function in
society with a condition. The views expressed by the PIO
representatives are in concordance with recent calls for a
more “humanistic” medicine that approaches the patient
as a whole person with a personal history, emotions, be-
liefs and sufferings [38]. A humanistic doctor takes the
time to listen to the patient’s story, shows compassion and
empathy, makes sure that the patient feels valued and
respected, and takes into consideration the patient’s per-
sonality and experience in the process of medical care. As
the PIO representatives repeatedly emphasized during our
interviews, no technological advancement or biological in-
strument can substitute the importance of the doctor-
patient relationship.
PM aims to strengthen dialogue and collaboration
between doctor and patient through increased patient
engagement [8]. In accounts of PM, patients are encour-
aged to discuss various treatment options with their
healthcare provider, communicate about their prefer-
ences, values and lifestyle, and provide feedback on
health care processes and outcomes [8]. At such, patient
engagement may be a critical strategy to enable the
provision of health care that is responsive to the patient’s
specific needs and situation as envisioned by the PIO
representatives. Patient engagement enables a better
power balance between patients and doctors, thus mak-
ing it easier for patients to express their concerns and
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preferences, and bring perspectives on their own care
[8]. However, while patient engagement strategies may
work for those patients who are eager to take responsi-
bility for their health care, seek knowledge and under-
stand the details of their clinical situation, they may not
be suitable for those who prefer to delegate the majority
of the responsibility for their health care to their health
care professional [8]. Similarly, some patients may not
have the ability to engage in their health, for instance be-
cause they lack the necessary health literacy to under-
stand what is at stake [39]. In this context, the PIOs that
have available resources and are willing to engage in PM
may have an important role to play in enhancing the
health literacy of patients and familiarizing them with
engagement strategies. Other patients may be so physic-
ally and mentally ill that they do not have the capability
to engage. For these patients, providing health care with
compassion and empathy may be particularly important;
time should be allocated in the PM agenda to enable
health care professionals to interact in a “humanistic”
manner with their patients.
Finally, our study results indicate that levels of aware-
ness regarding PM vary considerably between PIO repre-
sentatives. In general, the representatives from the larger
PIOs were more familiar with the concept of PM and
worked more mindfully toward PM than representatives
from smaller PIOs. Similarly, cancer PIOs were more
likely to integrate the concept or aspects of PM in their
strategy independent of their organizational size. Larger
PIOs may have more resources to investigate new med-
ical strategies than smaller PIOs which struggle with
basic issues such as guiding their patients through the
health care bureaucracy or educating health care profes-
sionals. Engaging in PM may be more challenging when
the organizations’ resources are limited. Similarly, the
general attention given to cancer in the PM discourse
and the fact that most targeted drugs that have been
marketed are cancer drugs [40] may explain why cancer
PIOs were generally more aware of PM than non-cancer
PIOs. As an illustration, several representatives from
non-cancer PIOs believed PM to be primarily focusing
on cancer to the disservice of other disease areas; a be-
lief previously observed among health care professionals
[41] and patient representatives [9]. It is therefore im-
portant that decision-makers work to increase levels of
awareness regarding PM among PIOs, and provide sup-
port to those PIOs that have limited resources and com-
petency but are willing to contribute to the PM agenda.
Conclusions
The development and realization of PM requires the in-
volvement of PIOs. Historically, PIOs have shown an im-
pressive ability to engender important changes on a
large scale that benefit patients. If the PIOs become
sufficiently convinced that PM is the future of medicine
and will benefit their patients, then they have the poten-
tial to play a significant role in driving the PM agenda
forward. It is therefore important that researchers,
health care funders, drug developers and policy makers
invite PIOs to the table, not only the biggest and most
influential PIOs but also the smaller ones should be en-
gaged so that PM is developed in ways that address the
“health care needs of patients. It is also important that
PIOs work together to become effective advocates of
PM. The European Patients’ Academy (EUPATI), a pan-
European platform for patients and PIO engagement,
may be a potential springboard for intra-PIO collabora-
tions [42]. The European Alliance for Personalised
Medicine (EAPM) [43], a coalition bringing together
European healthcare experts and patient advocates, may
also be one of the central arenas where PIOs could
discuss with key stakeholders issues related to priority
setting and resource allocation. Such models of collabor-
ation and engagement are needed to give PIOs an in-
creased opportunity to contribute to the decision making
process regarding the design of PM.
Study limitations
The results from our study provide insights into how
PIOs working within a range of diseases perceive PM
and reflect upon the PM agenda. Deciding on which
PIOs to include in our study was challenging: there are
thousands of active PIOs and they vary widely in
organizational structure, areas of activity and funding. It
was difficult to learn about the PIOs organizational and
financial structure on the basis of the information they
provide on their web site. In the absence of obvious cri-
teria to select PIOs, we decided to restrict our sampling
to non-profit PIOs that were disease-specific and were
either member of the European Patients’ Forum, or were
within the network of the Norwegian Cancer Genomics
Consortium. This was a pragmatic choice that enabled
us to come in contact with a variety of PIOs. However,
our sampling may not be representative of the wider
spectrum of PIOs that exist, and the PIOs situation (e.g.
relationship to biopharmaceutical companies) could have
to some extent influenced their interest in and level of
knowledge about PM.
For many of the PIO representatives, this study was
the first time they discussed PM and they were therefore
not able to provide any concrete examples of issues
related to their experience with PM, or specific recom-
mendations regarding their potential role in the realization
of PM. More work may be needed to investigate how a
larger spectrum of PIOs which have specifically endorsed
the concept of PM in their strategies, and work actively
toward it, envision their role in the realization of PM
agenda.
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